PSYENCE BIOMEDICAL LTD.
PBMNext catalyst
Psilocybin therapy
Adjustment Disorder
Get an email about PBM's next catalysts
Track PSYENCE BIOMEDICAL (PBM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
Psilocybin therapy Phase 2 Est. Readout
Primary completion for Psilocybin therapy trial (NCT07072728) in Adjustment Disorder
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Psilocybin therapy | Phase 2 | Adjustment Disorder | - | - |
Frequently asked questions
What is in PSYENCE BIOMEDICAL LTD.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PSYENCE BIOMEDICAL LTD.'s (PBM) pipeline across Phase 2. Its lead program is Psilocybin therapy (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PSYENCE BIOMEDICAL LTD.'s next FDA catalyst?→
PSYENCE BIOMEDICAL LTD.'s (PBM) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PBM biotech catalysts?→
Add PBM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PSYENCE BIOMEDICAL LTD.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.